Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice TargetHot
Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $772 to $780.
Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $772 to $780.